Abstract:Therapies that treat while diagnosing — theranostics — can extend length of survival and improve the quality of life for some people with advance-stage cancer. Therapies that treat while diagnosing — theranostics — can extend length of survival and improve the quality of life for some people with advance-stage cancer.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: How to provide more effective treatment options with fewer side effects for patients with advanced cancer, especially for those who have received multiple traditional treatments (such as chemotherapy, radiotherapy, and surgery) but with limited effectiveness or serious side effects. Specifically, the article focuses on a new treatment method - **Theranostics**, especially the application of the drug **Pluvicto (177Lu - PSMA - 617)** in the treatment of metastatic prostate cancer.
### Specific background of the problem
1. **Limitations of traditional treatment methods**:
- Although traditional treatment methods such as chemotherapy and radiotherapy are effective in some cases, they often bring serious side effects, such as fatigue, nerve damage, etc., which seriously affect the patient's quality of life.
- For advanced prostate cancer patients like Steve Reed, after multiple chemotherapy sessions, their physical condition gradually deteriorates and their quality of life significantly declines.
2. **Need for new treatment methods**:
- A treatment method that can prolong the patient's survival time while reducing side effects and improving the quality of life is required.
- Especially for those patients who have received multiple traditional treatments but with poor results, new treatment means are urgently needed.
### Mechanism of action of Pluvicto
Pluvicto is a **radioisotope therapy**, and its working principle is as follows:
- **Targeted recognition**: The molecules in Pluvicto can specifically recognize and bind to a specific protein on the surface of prostate cancer cells - **Prostate - Specific Membrane Antigen (PSMA)**.
- **Radioactive killing**: Once bound to cancer cells, the radioactive isotope **177Lu** carried by Pluvicto will release β - particles, which directly enter the cancer cells, destroy their DNA, and thus kill the cancer cells.
- **Low side effects**: Since this treatment method can accurately target cancer cells, it causes less damage to normal tissues and has relatively fewer side effects.
### Significance of the research
By introducing new radioisotope therapies such as Pluvicto, researchers hope to make progress in the following aspects:
1. **Improve quality of life**: For advanced cancer patients, Pluvicto can significantly reduce the side effects brought by traditional treatment methods, enabling patients to enjoy life better.
2. **Prolong survival time**: Clinical trials show that the median survival time of patients treated with Pluvicto is about 4 months longer than that of the control group.
3. **Expand the scope of application**: The research also explores whether Pluvicto can be used for other types of cancer, such as triple - negative breast cancer, which provides broad prospects for future research.
In general, this paper aims to explore how to use new radioisotope therapies, especially Pluvicto, to provide better treatment options for advanced cancer patients, thereby improving their quality of life and prolonging their survival time.